Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Sells S. Pneumoniae Patents to Aventis, Ends Research for Amgen

NEW YORK, Jan. 9 (GenomeWeb News) - GenomeTherapeutics has sold its pending Streptococcus pneumoniae patent applications to Aventis Pasteur, the company said today.


Aventis Pasteur, the vaccines business of Aventis, paid Genome Therapeutics $3 million for the U.S. patent applications, which relate to gene and protein sequences from the S. pneumoniae genome. Genome Therapeutics, based in Waltham, Mass., will retain certain rights relating to its pathogen genetic sequence database and its infectious disease diagnostics development program.


In addition, Genome Therapeutics said it has concluded a bone disease research project with Amgen, which led to the discovery of a novel gene. The company, which announced its plan to merge with Genesoft Pharmaceuticals in November, said it continues to reduce its investment in early-stage discovery research projects.


The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.